Who are Adefor dipivoxil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Telbivudine treatment, Baraclude Tab.®, Besifovir dipivoxil, Hepsera and lamivudine, Telbivudine (Standard of Care), blank Baraclude tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adefor-dipivoxil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Adefor dipivoxil — Competitive Intelligence Brief

Adefor dipivoxil (Adefor dipivoxil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide reverse transcriptase inhibitor. Area: Virology / Hepatology.

marketed Nucleotide reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Adefor dipivoxil (Adefor dipivoxil) — GlaxoSmithKline. Adeforvir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks viral replication in hepatitis B by inhibiting the reverse transcriptase enzyme.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Adefor dipivoxil TARGET	Adefor dipivoxil	GlaxoSmithKline	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase
Telbivudine treatment	Telbivudine treatment	Southeast University, China	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
Baraclude Tab.®	Baraclude Tab.®	Dong-A ST Co., Ltd.	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase
Besifovir dipivoxil	Besifovir dipivoxil	IlDong Pharmaceutical Co Ltd	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase
Hepsera and lamivudine	Hepsera and lamivudine	University of Washington	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase
Telbivudine (Standard of Care)	Telbivudine (Standard of Care)	Nanfang Hospital, Southern Medical University	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase
blank Baraclude tablets	blank Baraclude tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide reverse transcriptase inhibitor class)

GlaxoSmithKline · 2 drugs in this class
IlDong Pharmaceutical Co Ltd · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Jiangxi Kvvit Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adefor dipivoxil — Competitive Intelligence Brief. https://druglandscape.com/ci/adefor-dipivoxil. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab